Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-alcoholic steatohepatitis drugs

Bristol-Myers Squibb (BMS) building

Positive data for BMS’ clazakizumab in arthritis

Phase II results indicate drug is as effective as AbbVie’s Humira

Bristol-Myers Squibb (BMS) building

BMS bounces back to form in Q3

New launches in cancer, diabetes and RA help recovery from patent expiries

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

- PMLiVE

Allergan’s Julia Kendrick recognised as Young Achiever

Stood out in a hotly contested category at the Communiqué Awards 2013

- PMLiVE

Allergan appoints Douglas Ingram as first president

Promotion for company veteran

- PMLiVE

BMS appoints Dinesh Paliwal to board

He is CEO of audio firm Harman International

- PMLiVE

Setback for AZ and BMS as Onglyza flunks cardiovascular trial

Diabetes drug fails to show benefit over placebo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links